Posted: 21 July 2025
Biointelect has been awarded $33 million by the Australian Government through the Medical Research Future Fund (MRFF) to deliver a new national incubator designed to fast-track the commercialisation of research in vaccines and immune-based therapies. The funding was granted under the 2024 BioMedTech Incubator (BMTI) programme and marks one of the largest single investments in a life sciences-focused commercialisation initiative.
The new incubator, Biointelect Venturer, will operate as a national virtual platform to support Australian small-to-medium enterprises and early-stage innovators working in infectious disease prevention and treatment. Areas of focus include next-generation vaccines, immunotherapies, and technologies to combat threats such as influenza, COVID-19, HIV, tuberculosis, and antimicrobial resistance.
“We are honoured to be entrusted with this significant investment to support the next wave of vaccine and immunotherapy innovation in Australia,” said Leah Goodman, CEO of Biointelect. “Through Biointelect Venturer, we aim to help bridge the gap between great science and real-world impact by providing targeted commercialisation support to high-potential ventures.”
The incubator will focus on building commercial capability and investment readiness within the sector, with an emphasis on retaining IP and talent within Australia. It will also engage with public health experts, community stakeholders, and investors to align scientific innovation with national health priorities.
“Accelerating the translation of Australian research into accessible health solutions requires more than funding — it takes coordinated support, strategic networks, and a clear commercial pathway,” said Jennifer Herz, Founder and Executive Director of Biointelect. “This initiative will help unlock that potential at a national scale.”
Biointelect Venturer is expected to commence operations in early 2026 following broad consultation with key stakeholders. The incubator will play a central role in strengthening Australia’s position as a global leader in vaccine and immunotherapy innovation.
For more information click here.
